These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20606377)

  • 1. Relation between cooling sheet effect and tear histamine concenration in allergic conjunctivitis.
    Hirakawa N; Yanoshita R; Yoshii M; Yano H
    Yakugaku Zasshi; 2010 Jul; 130(7):971-5. PubMed ID: 20606377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The early efficacy of topical levocabastine in patients with allergic conjunctivitis.
    Fujishima H; Fukagawa K; Takano Y; Okamoto S; Nakagawa Y; Uchio E; Yokoi N; Fukushima A; Takamura E
    Allergol Int; 2006 Sep; 55(3):301-3. PubMed ID: 17075271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
    Tagawa Y; Namba K; Nakazono Y; Iwata D; Ishida S
    Allergol Int; 2017 Apr; 66(2):338-343. PubMed ID: 27720602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
    Verin P; Easty DL; Secchi A; Ciprandi G; Partouche P; Nemeth-Wasmer G; Brancato R; Harrisberg CJ; Estivin-Ebrardt C; Coster DJ; Apel AJ; Coroneo MT; Knorr M; Carmichael TR; Kent-Smith BT; Abrantes P; Leonardi A; Cerqueti PM; Modorati G; Martinez M
    Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of allergic conjunctivitis by thermography.
    Hara Y; Shiraishi A; Yamaguchi M; Kawasaki S; Uno T; Ohashi Y
    Ophthalmic Res; 2014; 51(3):161-6. PubMed ID: 24603108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients.
    Leonardi A; Bremond-Gignac D; Bortolotti M; Violato D; Pouliquen P; Delval L; Grouin JM; Fregona IA
    Br J Ophthalmol; 2007 Dec; 91(12):1662-6. PubMed ID: 17585003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antihistamine eye drops on the conjunctival provocation test with Japanese cedar pollen allergen.
    Dake Y; Enomoto T; Cheng L; Enomoto K; Shibano A; Ikeda H; Yoda S; Yajin S; Sakota T; Yamanishi E
    Allergol Int; 2006 Dec; 55(4):373-8. PubMed ID: 17130679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test].
    Allaire C; Siou-Mermet R; Bassols A
    J Fr Ophtalmol; 2012 Sep; 35(7):491-8. PubMed ID: 22498504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA; Leahy C; Krenzer KL
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis.
    Fujishima H; Fukagawa K; Tanaka M; Uchio E; Takamura E; Nakagawa Y; Miyazaki D; Fukushima A; Okamoto S; Yokoi N
    Ophthalmologica; 2008; 222(4):232-9. PubMed ID: 18463425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
    Abelson MB; George MA; Schaefer K; Smith LM
    J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats.
    Minami K; Hossen MA; Kamei C
    Biol Pharm Bull; 2005 Mar; 28(3):473-6. PubMed ID: 15744071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
    Villareal AL; Farley W; Pflugfelder SC
    Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.
    Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E
    Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
    Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
    Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms.
    Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK
    J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis.
    Bilkhu PS; Wolffsohn JS; Naroo SA; Robertson L; Kennedy R
    Ophthalmology; 2014 Jan; 121(1):72-78. PubMed ID: 24070810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis.
    Giede C; Metzenauer P; Petzold U; Ellers-Lenz B
    Curr Med Res Opin; 2000; 16(3):153-63. PubMed ID: 11191004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.